Sobierajski Tomasz, Lasek-Bal Anetta, Krzystanek Marek, Gilhus Nils E
The Center of Sociomedical Research, Faculty of Applied Social Sciences and Resocialization, University of Warsaw, Warsaw, Poland.
Department of Neurology, School of Health Sciences, Medical University of Silesia in Katowice, Katowice, Poland.
Front Neurol. 2023 Aug 4;14:1214041. doi: 10.3389/fneur.2023.1214041. eCollection 2023.
The survey aimed to explore patients' perspectives with myasthenia gravis (MG) toward the diagnosis made and the therapy used to treat MG. The survey was conducted with a quantitative method, using the CAWI technique. A total of 321 people participated in the survey. More than half of the respondents (56.4%) had suffered from MG for less than 10 years. In three out of 10 cases (30.9%), the diagnosis of MG lasted 3 years or longer. The diagnostic delay was significantly longer in female respondents than in the males ( = 0.029). Cholinergic drugs were used in 92.9% of cases initially, and as maintenance therapy in 84.3% of cases. Corticosteroids were used in initiating therapy (45.8%) and as maintenance therapy (46.4%). One in four respondents (25.5%) reported experiencing very strong and strong side effects after using steroids. The side effects from steroid therapy very strong or strong affected overall physical health in 55.9% of respondents, very strong or strong affected self-acceptance in 52%, to a very large or large extent on mental health in 47.1%, and to a very strong or strong extent influenced the performance of daily activities in 28.2%. More than half of the respondents (57.0%) had had a thymectomy. Seven out of 10 respondents (72.0%) declared that the therapy they were on at the time of the survey allowed them (to varying degrees) to control their course of MG. Low therapy acceptance and less well controlled MG was associated with a preference for non-tablet therapies ( = 0.045). Regular follow-up and cooperation with the specialist health care system should improve MG symptoms, activities of daily living, and quality of life.
该调查旨在探究重症肌无力(MG)患者对所做出的诊断以及用于治疗MG的疗法的看法。该调查采用定量方法,运用计算机辅助网络调查(CAWI)技术。共有321人参与了此次调查。超过一半的受访者(56.4%)患MG的时间不到10年。在十分之三的病例(30.9%)中,MG的诊断持续了3年或更长时间。女性受访者的诊断延迟明显长于男性(P = 0.029)。92.9%的病例最初使用了胆碱能药物,84.3%的病例将其用作维持治疗。45.8%的病例在起始治疗时使用了皮质类固醇,46.4%的病例将其用作维持治疗。四分之一的受访者(25.5%)报告称在使用类固醇后出现了非常强烈和强烈的副作用。类固醇治疗产生的非常强烈或强烈的副作用在55.9%的受访者中影响了整体身体健康,在52%的受访者中影响了自我接受程度,在47.1%的受访者中对心理健康有很大或较大程度的影响,在28.2%的受访者中对日常活动表现有非常强烈或强烈的影响。超过一半的受访者(57.0%)接受了胸腺切除术。十分之七的受访者(72.0%)表示,他们在调查时所接受的治疗(在不同程度上)使他们能够控制MG的病程。治疗接受度低和MG控制不佳与对非片剂疗法的偏好有关(P = 0.045)。定期随访以及与专科医疗保健系统合作应能改善MG症状、日常生活活动能力和生活质量。